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Preventing damage limitation: 
targeting DNA-PKcs and DNA 
double-strand break repair pathways 
for ovarian cancer therapy
Daniela A. Dungl† , Elaina N. Maginn*† and Euan A. Stronach
Molecular Therapy Laboratory, Department of Surgery and Cancer, Ovarian Cancer Action Research Centre, Imperial 
College London, London, UK
Platinum-based chemotherapy is the cornerstone of ovarian cancer treatment, and its 
efficacy is dependent on the generation of DNA damage, with subsequent induction of 
apoptosis. Inappropriate or aberrant activation of the DNA damage response network is 
associated with resistance to platinum, and defects in DNA repair pathways play critical 
roles in determining patient response to chemotherapy. In ovarian cancer, tumor cell 
defects in homologous recombination – a repair pathway activated in response to dou-
ble-strand DNA breaks (DSB) – are most commonly associated with platinum-sensitive 
disease. However, despite initial sensitivity, the emergence of resistance is frequent. 
Here, we review strategies for directly interfering with DNA repair pathways, with par-
ticular focus on direct inhibition of non-homologous end joining (NHEJ), another DSB 
repair pathway. DNA-dependent protein kinase catalytic subunit (DNA-PKcs) is a core 
component of NHEJ and it has shown considerable promise as a chemosensitization 
target in numerous cancer types, including ovarian cancer where it functions to promote 
platinum-induced survival signaling, via AKT activation. The development of pharma-
cological inhibitors of DNA-PKcs is on-going, and clinic-ready agents offer real hope to 
patients with chemoresistant disease.
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OvARiAN CANCeR AND CHeMOReSiSTANCe
Ovarian cancer is the seventh most common cancer amongst women worldwide with an incidence 
of 6.1 [age-standardized rate (ASR)] per 100,000, and a mortality rate of 3.7 (ASR) (1). It is the fifth 
highest cause of cancer-related deaths among women, accounting for more deaths than any other 
cancer of the female reproductive system. Ovarian cancers are classified into a number of subtypes: 
serous, mucinous, endometrioid, clear cell, transitional, squamous, mixed, and undifferentiated 
subtypes (2). Further classification is by histopathological grade, with grade (borderline, grades 
1–3) associated with how quickly the tumor is likely to grow. Well differentiated or low-grade (type 
I) tumors are typically indolent, slow growing tumors that are often detected at early stages, and 
include low-grade serous, low-grade endometrioid, clear cell, and mucinous carcinomas. Poorly 
differentiated or high-grade (type II) disease includes high-grade serous, high-grade endometrioid, 
mixed mesodermal (carcinosarcoma), and undifferentiated carcinomas that tend to grow and spread 
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more quickly (3). The majority of patients (~70%) with ovarian 
cancer are diagnosed with late stage high-grade serous epithelial 
ovarian cancer (HGSOC), with dissemination of primary tumor 
throughout the peritoneal cavity in most cases, and the 5-year 
survival for these patients is <50% (4–6).
Standard therapy for advanced ovarian cancer usually involves 
surgical debulking of the tumor mass followed by chemotherapy, 
including a platinum-containing compound. Optimal tumor 
debulking is critical, as postoperative residual disease strongly 
influences patient outcome (7). First-line chemotherapy for ovar-
ian cancer is typically carboplatin, or under certain circumstances 
cisplatin, given either alone or, more commonly, in combination 
with paclitaxel (8). Response rates to first-line therapy are favora-
ble; however, the relapse rate is high. The platinum-free interval 
(PFI: i.e., interval between end of chemotherapy and relapse) is 
a good indicator of response to subsequent treatment with plati-
num: >12 month PFI predicts favorable response to retreatment; 
6–12 month PFI is regarded as “intermediate”; <6 month PFI is 
defined as platinum resistant with commensurate poor response 
rate to retreatment with platinum (9, 10). Other chemotherapeu-
tic options, typically used following platinum-resistant relapse, 
include topotecan (topoisomerase inhibitor), liposomal doxo-
rubicin (inhibitor of DNA replication), gemcitabine (replaces 
cytidine during DNA replication leading to tumor growth 
arrest), and etoposide (forms ternary complexes with DNA and 
topoisomerase II causing DNA strand breaks), however response 
rates to such alternatives remain dismal. Accordingly, elucidation 
of mechanisms underpinning platinum resistance is an urgent 
priority and may allow the development of precision strategies 
to reverse resistance.
The biochemical mechanisms of cytotoxicity of cis- and 
carboplatin involve their binding to DNA and non-DNA targets 
and induction of cell death through apoptosis, necrosis, or both, 
within the heterogeneous population of tumor cells (11, 12). 
Direct binding to genomic DNA (gDNA) can result in a number of 
lesions: the initial lesion formed is bulky platinum-DNA adducts 
that can mediate intra- and inter-strand crosslinks. If these are 
not removed but are encountered by the cells’ transcription or 
replication machinery, stalling of these processes can lead to 
the generation of DNA breaks, either single-strand DNA breaks 
(SSB) or double-strand DNA breaks (DSB). In response to such 
DNA damage, a cell can either initiate repair, or if the damage is 
too severe, cell cycle arrest, and/or apoptosis are initiated. This 
process is required for a successful chemotherapeutic response. 
Non-DNA targets of cis- and carboplatin include components 
of the cell membrane lipid bilayer, such as phospholipids and 
phosphatidylserine, and cytoplasmic targets such as cytoskeletal 
microfilaments, thiol-containing peptides, proteins, and RNA 
(11, 13). Furthermore, these compounds can alter the activity 
of enzymes, receptors, and other proteins through coordination 
to sulfur atoms of cysteine and/or methionine residues and to 
nitrogen atoms of histidine residues (14). However, the forma-
tion of adducts on gDNA are thought to be the primary lesion 
underlying the cytotoxic effect of these drugs.
Given the range of targets of cis- and carboplatin, it is not 
surprising that resistance of ovarian cancer to these compounds 
is multifactorial and has been reported to involve increased 
drug inactivation and efflux, decreased drug influx, increased 
cellular glutathione and metallothionein levels, alterations in 
cell cycle control, oncogene expression, changes in apoptotic 
threshold, and increased or inappropriate activation of DNA 
repair pathways (9, 15, 16). Although only 5–10% of covalently 
bound cell-associated cisplatin is found in the gDNA, targeting 
the DNA repair process has shown considerable promise as a 
therapeutic strategy for platinum-resistant ovarian cancer. Here, 
we review the DNA repair network as a strategic and rational tar-
get for therapeutic intervention in ovarian cancer. In particular, 
we highlight the non-homologous end joining (NHEJ) pathway 
as an under-explored target for therapeutic discovery and use 
DNA-dependent protein kinase catalytic subunit (DNA-PKcs) as 
an example of how this pathway can be targeted therapeutically 
(see Figure 1 for graphical summary and Table 1 for a summary 
of the key messages).
DNA RePAiR PROTeiNS AS 
THeRAPeUTiC TARGeTS
The generation of DNA damage is not an exclusive effect of 
chemotherapeutic agents, and occurs in response to numerous 
“natural” events such as replication errors or the production 
of reactive oxygen species after exposure to UV light. In order 
to respond to the various types of damage that can occur, cells 
possess an arsenal of DNA repair mechanisms, listed in Table 2. 
A more detailed description of these processes and their key 
components is reviewed elsewhere (17). Although DNA repair 
pathways are crucial for normal cell survival, defects in the execu-
tion and control of these mechanisms have been linked both with 
the development of cancers and response to chemotherapy. In 
particular, defects in nucleotide excision repair (NER), mismatch 
repair (MMR), and DSB repair pathways have been linked to 
platinum sensitivity and resistance (18, 19). Ovarian cancer 
together with pancreatic and breast cancers have been defined as 
the top three cancers in which DNA repair pathways are defective 
(20). As such, disruption of these pathways has been identified as 
a strategic approach to increase therapeutic responses to DNA-
damaging agents (21–23).
HOMOLOGOUS ReCOMBiNATiON RePAiR 
DeFiCieNCY iS ASSOCiATeD wiTH 
CHeMOReSPONSe
Homologous recombination (HR) is one of the major pathways 
for repair of DSBs, and requires an intact sister chromatid to 
use as a template to repair the damage. As such, it is restricted 
to the S and G2 phases of the cell cycle. HR deficiency (HRD) 
most commonly occurs in HGSOC, and is detected in 44% of 
these patients (24). In addition, HR defects have been suggested 
to drive HGSOC development (25). The majority of HRD is 
linked to germline or somatic alterations in the HR-associated 
genes BRCA1 and BRCA2 (~20% mutation; 10% methylation) 
(6, 24). Germline mutations in these genes represent significant 
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risk factors for developing HGSOC: for a woman with a BRCA1 
mutation, the risk of developing epithelial ovarian cancer is 
39–46%, and with a BRCA2 mutation, 12–20% (26). HRD 
phenotype is also associated with sensitivity to platinum-based 
chemotherapy. Additionally, these patients are responsive to 
poly(ADP-ribose) polymerase (PARP) inhibitors, which are the 
most successful drugs targeting DNA repair proteins developed 
to date. PARP functions in the base excision repair (BER) path-
way to repair SSBs, and inhibitors have been found to stabilize or 
regress ovarian cancer with BRCA1/BRCA2 mutations (27–29). 
The biological basis for this is synthetic lethality due to loss of 
both BER and HR, resulting in simultaneous inhibition of SSB 
and DSB repair. The PARP inhibitor Olaparib was approved by 
the European Union for maintenance treatment of BRCA mutant, 
platinum-sensitive ovarian cancer in December 2014; the first-
in-class approval for a PARP inhibitor. However, some patients 
without BRCA1/2 mutations also respond to PARP inhibition, 
implying the presence of other HR defects. For example, BRCA 
pathway inactivation may also occur through methylation 
of FANCF and/or EMSY amplification (30, 31). Additionally, 
RAD51 depletion has been found to sensitize ovarian cancer cells 
to PARP inhibitor-based combination chemotherapy (32). For a 
thorough review of strategies to target HR processes, or to exploit 
inherent deficiencies in associated genes, with the aim of improv-
ing ovarian cancer response to platinum-based chemotherapy, 
see Wiedemeyer et al. (33).
DNA repair defects other than BRCA mutations are also prob-
able influencers of platinum sensitivity in HGSOC; we and others 
have previously described a BRCA2 reversion mutation, which 
does not equate to full cisplatin resistance in a HGSOC cell line 
series (34). The PEO1/4 cell line set were initially derived from 
a HGSOC patient during the platinum-sensitive and -resistant 
phases of the disease, respectively (35). This patient presented 
with a germline BRCA2 truncating mutation, which was absent 
in the platinum-resistant PEO4 cell line. However, reversion of 
this mutation has been reported in PEO1 cells, by us and others 
(34, 36), and although this restores BRCA2 functionality, the 
platinum-resistant phenotype is not fully recapitulated; indeed, 
we have reported a 10-fold difference in cisplatin IC50 values 
between BRCA revertant PEO1 cells and PEO4 cells (34). Based 
on this, a continuum of platinum sensitivity can be proposed: 
from extreme (HR defective/BRCA mutant) to intermediate 
(HR competent i.e., BRCA revertant) to resistant (i.e., active 
resistance mechanisms). These latter mechanisms may be driven 
FiGURe 1 | Graphical summary: DNA repair proteins such as DNA-PKcs can be targeted to improve outcomes for patients with ovarian cancer. 
Ovarian cancers with defects in the homologous recombination (HR) pathway are initially sensitive to platinum treatment, and also respond to Olaparib that targets 
the base excision repair pathway protein PARP. For the majority of cases, which are HR proficient, platinum-based chemotherapy is still utilized but resistance is 
likely. For patients with platinum-resistant disease, inhibition of DNA-PKcs, a key component of the non-homologous end joining pathway, represents a targeted 
approach to prevent the pro-survival AKT and anti-apoptotic signaling associated with resistance.
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by components of other DNA repair pathway components, 
for example, DNA-PKcs that drives AKT survival signaling in 
HGSOC (37), and will be discussed now.
DNA-PKcs AS A THeRAPeUTiC TARGeT 
FOR OvARiAN CANCeR
DNA-PKcs Structure and Regulation
In comparison to HR that is restricted to post-DNA replication 
phases of the cell cycle, the NHEJ pathway can respond to DSBs 
throughout the cell cycle. This is due to its lack of requirement 
for a template DNA strand to use in repair. A key mediator of 
NHEJ is DNA-PKcs, a DNA-activated serine/threonine protein 
TABLe 1 | Section summary and key “take home” messages.
Section Key messages
1. Ovarian cancer and 
chemoresistance
•	 Ovarian	cancer	is	the	most	lethal	gynecological	
malignancy.
• Resistance to platinum-based chemotherapy 
is a major obstacle to treating patients with 
ovarian cancer.
2. DNA repair proteins 
as therapeutic 
targets
• DNA damage repair proteins are rational but 
understudied targets for developing strategies 
to overcome platinum resistance.
3. Homologous 
recombination 
repair deficiency 
is associated with 
chemoresponse
• Defects in homologous recombination are 
associated with high risk of developing ovarian 
cancer.
• These defects may also be used as 
theranostic markers of response to platinum- 
and PARP inhibitor-based chemotherapies.
4. DNA-PKcs as a 
therapeutic target 
for ovarian cancer
• DNA-PKcs is a core mediator of the non-
homologous end joining pathway, which 
functions to repair DNA double-strand breaks.
• Post-translational modifications and protein–
protein interactions regulate DNA-PKcs activity.
• DNA-PKcs inhibition has been widely 
associated with restoring radio- and chemo-
sensitivity in a range of cancers.
• DNA-PKcs inhibitors developed to date are 
largely unsuitable for clinical use.
5. DNA-PKcs inhibition 
as a platinum 
sensitization 
strategy
• DNA-PKcs inhibition shows considerable 
promise as a strategy for reversing platinum 
resistance in ovarian cancer.
TABLe 2 | DNA repair pathways and associated lesions.
Repair pathway Activated in response to
Nucleotide excision repair (NER) Bulky- and helix-distorting adducts
Base excision repair (BER) Non-helix-distorting base lesions and SSBs
Mismatch repair (MMR) Incorrect insertion, deletion, and base 
misincorporation
Non-homologous end joining 
(NHEJ)
DNA DSBs
Homologous recombination (HR) DNA DSBs
kinase that is abundantly expressed in almost all mammalian 
cells. DNA-PKcs is a member of the phosphatidylinositol-3-OH 
kinase (PI(3)K)-related protein (PIKK) superfamily, and is 
encoded on chromosome 8q11.21 by the PRKDC gene with a 
size of 187.07 kb and 86 exons. The DNA-PKcs protein consists of 
4129 amino acids (~469 kDa), and contains a number of regions, 
including a catalytic domain and DNA-binding and Ku-binding 
domains (38).
DNA-PKcs functions as the catalytic subunit of the DNA-PK 
holoenzyme, which although best known for its role in NHEJ 
has other reported roles, including regulating apoptosis, 
maintaining telomere length, cell cycle control, and regulation 
of mitochondrial protein function (39–41). The holoenzyme is 
composed of DNA-PKcs and the Ku70/80 proteins. These are 
not constitutively associated; instead the holoenzyme is assem-
bled in response to contact with DNA. The ring-like structure 
of the Ku70/80 dimer first binds to the DNA break, encircling 
the end and allowing the dimer to translocate along the duplex. 
DNA-PKcs is then recruited, and the complex acts as a scaffold, 
providing binding sites for downstream components of NHEJ. 
The kinase activity of DNA-PKcs is activated following its asso-
ciation with both the Ku70/80 dimer and a DNA terminus and 
autophosphorylation triggers a conformational change leading 
to the release of the DNA ends, making them available to other 
factors participating in DNA end-processing or ligation. As 
such, DNA-PKcs functions as a “gatekeeper” to protect DNA 
ends from premature processing, ligation, and degradation 
until the two broken ends are properly positioned (42–44). 
Although DNA-PKcs is most potently activated in response 
to DSBs, DNA-independent activation of DNA-PKcs due to 
its interaction with other proteins has also been reported, e.g., 
C1D, HSF1, and Lyn (45–47). The physiological significance 
of these DNA-independent activities of DNA-PKcs is less well 
understood.
DNA-PKcs contains multiple phosphorylation sites, and mod-
ifications to these alter the activity, conformation, and stability 
of the protein. Autophosphorylation events are initiated follow-
ing binding of DNA-PKcs to DNA, and function reciprocally to 
coordinate the control of NHEJ. For example, phosphorylation 
at the ABCDE cluster, located between Thr2609 and Thr2647, 
promotes DNA end-processing, whereas phosphorylation at 
the PQR cluster between Ser2023 and Ser2056 prevents this by 
decreasing accessibility. End-processing of complex DSBs (e.g., 
hairpins) also requires trans-phosphorylation of DNA-PKcs by 
ATM, and this serves to recruit the endonuclease Artemis to 
the site of damage. Subsequent to this, autophosphorylation 
is required to remove DNA-PKcs in order for end-ligation to 
proceed (48). Autophosphorylation of DNA-PKcs at its extreme 
N terminus, on Ser56 and Ser72, may be involved in holoen-
zyme complex stability, while phosphorylation in the T-loop 
of the kinase domain at Thr3950 results in kinase inactivation 
without affecting complex stability. DNA-PKcs phosphoryla-
tion may also affect DSB repair pathway choice: cells deficient 
in DNA-PKcs show increased HR-mediated repair of DSBs, 
and autophosphorylation of DNA-PKcs at the Thr946 and 
Ser1004 cluster seems to serve as a switch between NHEJ and 
HR (49–51).
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The choice of pathway may additionally be affected by the 
interaction of DNA-PKcs with other proteins. For example, 
the kinase and proto-oncogene c-Abl is phosphorylated by 
ATM in response to ionizing radiation (IR) and certain other 
DNA-damaging agents, and has been shown to interact with 
DNA-PKcs. Phosphorylation of DNA-PKcs by c-Abl inhibits its 
ability to form a complex with DNA, whereas phosphorylation 
of c-Abl by DNA-PKcs potentially activates c-Abl kinase activ-
ity in response to IR exposure. This suggests the existence of an 
autoregulatory negative feed-back loop that might lead to repres-
sion of DNA-PKcs activity after the appropriate DNA damage 
signaling and/or repair pathways have been initiated (52). The 
protein kinase activity of DNA-PKcs can also be stimulated by 
PARP independently of the Ku70/80 complex (53) suggesting 
that PARP, in addition to its key role in BER, may additionally 
facilitate DNA DSB repair via regulation of DNA-PKcs.
A number of mechanisms by which DNA-PKcs activity is 
attenuated have been reported. DNA-PKcs inactivation via cleav-
age by the ICE family cysteine proteases, for example, caspase-3, 
may occur in apoptotic cells to prevent repair of the fragmented 
gDNA that is produced during the final steps of the apoptotic 
pathway (54, 55). Degradation of DNA-PKcs via an ubiquitin-
mediated proteasome pathway has also been reported following 
Herpes simplex virus type 1 infection, possibly as a mechanism 
for aiding virus replication (56).
DNA-PKcs and Chemoresistance
Numerous studies have shown a correlation between DNA-PKcs 
expression and activity with response to radio- and chemotherapy. 
This is unsurprising given that DNA-PKcs plays a crucial role in 
the repair of the DSBs generated by these treatments. Additionally, 
chemoresponse has been linked to other activities of DNA-PKcs, 
including cell cycle control and regulation of mitochondrial heat-
shock proteins (39, 41). However, predictive association of DNA-
PKcs expression/activity in human cancer is controversial and 
differs between stage and pathological type. For example, cells 
with defective DNA-PKcs activity show increased radiosensitiv-
ity, and in lung carcinoma cell lines after γ-irradiation, the lowest 
DNA-PKcs protein content and kinase activity was found in the 
most radiosensitive cells, U-1285 and H-69, while the highest 
was found in the most radioresistant cells U-1810 (57, 58). DNA-
PKcs activity in peripheral blood lymphocytes from untreated 
patients with advanced breast and uterine cervix cancers have 
been found to be significantly lower than in those with early stage 
disease. However, other studies have shown correlation between 
increased DNA-PKcs expression and advanced tumor stage. A 
genome-wide copy number and expression microarray analysis 
of gastric cancer revealed diverse chromosomal region altera-
tions for different stages or histological subtypes of this disease: 
copy number gains at chromosome 8q11-q24 were very frequent 
(63%) and candidate genes such as PRKDC showed co-regulation 
with increased expression levels (59).
Some relationship may exist between the NHEJ pathway and 
cellular sensitivity or resistance to DNA damage; however, this 
relationship does not appear to be universal and may be cell or 
tumor-type specific. No strong correlation between radiosensi-
tivity and DNA-PKcs was found in a study of sporadic human 
ovarian cancer cell lines. The data suggested that DNA-PKcs 
copy number, expression level, or kinase activities are not reliable 
predictors of radiosensitivity in ovarian cancer (60). However, 
inhibition of DNA-PKcs has been shown by us to reverse cisplatin 
resistance in a panel of ovarian cancer cell lines (37). This study 
used paired cell lines derived from patients before and after the 
emergence of platinum resistance. Interestingly, we found that 
DNA-PKcs inhibition did not increase the apoptotic effect of 
platinum in already sensitive cells. The mechanism underpinning 
the response to DNA-PKcs inhibition was shown to result from 
direct modulation of AKT survival signaling by DNA-PKcs. In 
platinum-resistant cells only, AKT was activated in response to 
cisplatin-mediated DNA damage by phosphorylation on serine 
473 by DNA-PKcs. This was prevented by DNA-PKcs inhibition 
and doing so reversed the platinum-resistant phenotype, identi-
fying a specific role for DNA-PKcs in mediating platinum resist-
ance in HGSOC. DNA-PKcs-driven AKT signaling has also been 
identified to underlie doxorubicin resistance in glioblastoma cell 
lines (61).
Pharmacological DNA-PKcs inhibitors
Despite the current lack of a robust predictive biomarker 
of response to DNA-PKcs inhibition, many small-molecule 
inhibitors for this protein have been developed. The chemistry 
of these compounds varies, and some of these have selectivity for 
DNA-PKcs while others are broad-range PI3K family member 
inhibitors. The most common PIKK proteins targeted by these 
compounds are mTOR, PI3K, ATM, and ATR. The first identified 
inhibitors of DNA-PKcs were the PI3K inhibitors wortmannin 
and the quercetin derivative LY294002. Wortmannin is a fungal 
metabolite, and was found to inhibit DNA-PKcs in a non-ATP-
competitive manner, to potentiate IR-induced cytotoxicity and 
to inhibit DSB repair at concentrations that inhibit DNA-PKcs 
activity. However, the IC50 required for this is ~2-fold higher 
than that required for PI3K inhibition, indicating the effects 
observed may be due to multiple protein targeting (62). The cell-
permeable compound LY294002, on the other hand, acts on the 
ATP-binding site of PI3K proteins and inhibits DNA-PKcs in a 
competitive manner. The apoptotic rate of X-ray irradiated HeLa 
cells after pre-treatment with LY294002 was found to be signifi-
cantly higher than that of untreated cells, with a prolonged G2/M 
delay also observed in these cells (63). IC87361 is a morpholino-
flavonoid that has been derived from LY294002, and which is 
50-fold more selective for DNA-PKcs than for PI3K and other 
kinases. It enhances radiation sensitivity in wild-type C57BL6 
mouse pulmonary endothelial cells but not in SCID mouse cells, 
which lack DNA-PKcs. Furthermore, it was found to increase 
irradiation-induced apoptosis in lung cancer and melanoma cells, 
and caused significant growth delay in Lewis lung carcinoma 
xenografts treated with radiation and IC87361 in comparison 
to tumors treated with radiation alone (64). Other compounds 
developed and that have been studied as radiosensitizers are 
PI-103 (65), IC86621 (66), and AMA37 (67).
Two of the most widely studied DNA-PKcs inhibitors are 
NU7026 and NU7441. NU7026 is an ATP-competitive inhibitor 
of DNA-PKcs which displays selectivity over other PIKK family 
enzymes. It was developed using LY294002 as a template, shows 
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a 60-fold greater potency against DNA-PKcs than PI3K, and is 
inactive against both ATM and ATR (IC50 0.23 μM for DNA-PK, 
13 μM for PI3K, >100 μM for ATM and ATR). It has been shown 
to sensitize mouse embryonic fibroblasts and Chinese hamster 
ovary cells to radiation in vitro, and is not cytotoxic itself (68, 69). 
Additionally, NU7026 has shown chemosensitization activity, 
and has been shown to have synergistic cytotoxic activity when 
combined with chlorambucil in chronic lymphocytic leukemia 
cells, and this chemosensitization was found to correlate with 
inhibition of DNA-PKcs phosphorylation (70). In pancreatic 
ductal adenocarcinoma cells, inhibition of NHEJ with NU7026 
has been shown to result in accumulation of DNA damage, inhi-
bition of growth, and ultimately apoptosis even in the absence of 
exogenous DNA-damaging agents (71). Our previous data have 
used NU7026 to demonstrate the potential of DNA-PKcs inhibi-
tion as a chemosensitization strategy in HGSOC cell lines derived 
from patients with clinically platinum-resistant disease (37).
NU7441 is more potent than NU7026, and is a specific inhibi-
tor of DNA-PKcs, with at least 100-fold selectivity for this enzyme 
compared to other PIKK family kinases (72, 73). NU7441 has 
been found to increase the response of many cancer cell types 
to both chemo- and radiotherapy (73–88). The specificity of this 
compound was initially illustrated by the finding that it increases 
chemo- and radiosensitivity in MO59 glioblastoma cells, but not 
in their DNA-PKcs-deficient MO59-J counterparts. However, 
the mechanism by which NU7441 increases drug sensitivity has 
recently been shown to also result from inhibition of multidrug-
resistance protein 1 (MDR1), resulting in increased nuclear 
accumulation of cytotoxic agents that are substrates for this drug 
efflux pump and thus adding complexity to the mechanistic 
interpretation of response data obtained using this compound 
(85). Interestingly, MDR1 upregulation itself has been associated 
with DNA-PKcs activity in glioblastoma cell lines with acquired 
doxorubicin resistance (61).
To date, only one pharmacological inhibitor of DNA-PKcs 
has been assessed clinically. CC-115 is a dual DNA-PKcs/mTOR 
inhibitor which has been used in a phase 1 trial for patients with 
advanced malignancies (NCT01353625; http://clinicaltrials.gov). 
The results of this study are expected in 2016. DNA-PKcs has 
also been targeted in another recently completed phase 1 trial, 
combining DT-01, a DSB mimetic, with radiation in metastatic 
melanoma (NCT01469455). DT-01 is comprised of small DNA 
molecules, known as Dbait, which sequester DNA-PKcs and 
PARP, thereby impairing the DNA repair response to radiotherapy 
(89). Intriguingly, DNA-PKcs has recently been identified as key 
protein downregulated in breast cancer stem cells in response to 
treatment with the broad spectrum antibiotic doxycycline (90). 
Moreover, this was associated with increased radiosensitivity 
and decreased mammosphere formation in vitro, and suggests a 
potentially immediate way to incorporate DNA-PKcs inhibition 
into clinical practice.
DNA-PKcs iNHiBiTiON AS A PLATiNUM 
SeNSiTiZATiON STRATeGY
Although the majority of HGSOC patients initially respond to 
platinum-based chemotherapy, the emergence of resistance is a 
major barrier to its long-term effectiveness. Therefore, identifying 
a targeted strategy to restore response may offer real promise in 
the treatment of this disease. As discussed here, DNA-PKcs inhi-
bition has been shown to be effective in restoring platinum cyto-
toxicity in HGSOC (37). 4,5-Dimethoxy-2-nitrobenzaldehyde 
(DMNB), a cell-permeable vanillin derivative has also been 
reported to sensitize A2780 human ovarian carcinoma cells to 
cisplatin via inhibition of DNA-PKcs (91). Loss of DNA-PKcs has 
also been associated with increased cisplatin response in cervical 
cancer and gliomas (92, 93). The therapeutic activity of DNA-
PKcs inhibition has also been linked to mechanisms independent 
of its role in DNA-damage repair, and with respect to restoring 
platinum sensitivity. This may partly be related to increased 
drug accumulation due to MDR1 protein inhibition; however, 
additionally, we have shown that DNA-PKcs is involved in 
DNA-damage-mediated activation of AKT cell survival signaling 
(37). In this study, we found that platinum exposure induces an 
AKT-dependent pro-survival DNA damage response in clinically 
platinum-resistant but not platinum-sensitive HGSOC. In this 
system, AKT is phosphorylated specifically on Ser473 by DNA-
PKcs in the nucleus of platinum resistant but not sensitive cells. 
Inhibition of DNA-PKcs or AKT, but not mTORC2, was found 
to restore platinum sensitivity. Together, these data indicate that 
DNA-PKcs inhibition might be a clinical useful strategy for the 
prevention of platinum-induced AKT activation without inter-
fering with normal glucose homeostasis. Although DNA-PKcs 
inhibitors are not yet ready for full clinical implementation, we 
have been able to test our laboratory hypothesis that preventing 
DNA-PKcs-mediated AKT signaling will reverse platinum resist-
ance clinically by using an AKT inhibitor. A clinical trial led by 
our center reported a 37% overall response rate to daily oral AKT 
inhibition using GSK2110183 in combination with six cycles of 
3-weekly carboplatin (AUC5) and paclitaxel (175 mg/m2) in clini-
cally platinum-resistant ovarian cancer: a patient group with an 
expected response rate to carboplatin/taxol of only 10–14% (94).
In vitro studies have also shown the potential of DNA-PKcs 
inhibition as a sensitizing strategy for platinum compounds in 
other cancers, including osteosarcoma, breast, and pancreatic (37, 
95, 96), and therefore development of such inhibitors may present 
broad clinical applicability. In particular, they may be particularly 
beneficial in lung cancer, where platinum resistance is also associ-
ated with aberrant DDR mechanisms (97). A role for DNA-PKcs 
in driving metastatic processes, i.e., angiogenesis, migration, and 
invasion, has been recently identified, suggesting an additional 
benefit of DNA-PKcs inhibitor-based chemotherapy in treating 
metastatic cancers (98).
The promise of PARP inhibition strategies and DNA-PKcs as a 
therapeutic target highlights the importance of understanding the 
clinical significance of the functioning and defective DNA repair 
mechanisms in cancer. There remains the need to identify reliable 
biomarkers of tumor cell response and resistance to therapies 
targeting DNA repair proteins and indeed to identify and validate 
new therapeutic targets from this critical but insufficiently mined 
resource. The identification of patient subgroups who will benefit 
most from such strategies is also required – DDR proteins such as 
DNA-PKcs have been suggested to have a tumor-suppressive role 
in the early stages of carcinogenesis where ineffective DDR may 
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contribute to the generation of genomic instability that drives 
tumor progression (99). As such, the development of DNA-PKcs 
inhibitions, and indeed other DDR targeted therapies, should be 
mindful of DNA damage thresholds that can be either oncogenic 
or tumor-suppressive, depending on the tumor stage. Together, 
such knowledge and understanding will translate into the devel-
opment of new directed strategies that will help overcome clinical 
platinum resistance in ovarian cancer, and by that reduce patient 
mortality.
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